Dow B. Hickam, Inc.
Executive Summary
$10 mil. annual sales pharmaceutical marketer in Sugar Land, Texas is "searching for new products we can leverage through our existing manufacturing and marketing capabilities." the firm says in its 1985 annual report. The company is essentially a one-product company, based on sales of Granulex, an aerosol medication for bed sores. A handwash/surgical scrub line, Neotec, purchased in 1983 is being delayed by a new drug argument, with FDA. The company says it is looking for already marketed products or "products the developers choose not to market for themselves." In 1985, the company had profits of $1.5 mil. and working capital of $7.4 mil
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.